Boardroom Alpha
Boardroom Alpha
EFOR · Current Report (Form 8-K) · Filed July 31, 2025

Everforth Inc — Current Report (Form 8-K)

Form
8-K
Filed
July 31, 2025
Period
Jul 31, 2025
Ticker
EFOR
Accession
0000890564-25-000042
Boardroom Alpha · Filing insights

ASGN borrows $100M incremental term loan under its credit facility, boosting liquidity for investments, acquisitions, and buybacks; due 2028.

About Everforth Inc
Market cap
$920M
1Y TSR
−61.4%
3Y TSR
−34.7%
Board grade
C-
Sector
Technology
CEO
Theodore S Hanson
Last annual meeting: Jun 11, 2026 · View full Everforth Inc profile →
asgn-20250731

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of report (Date of earliest event reported): July 31, 2025 (July 31, 2025)

ASGN Incorporated
(Exact name of registrant as specified in its charter)
 
Delaware 001-35636 95-4023433
(State or other jurisdiction
of incorporation)
 (Commission
File Number)
 (IRS Employer
Identification No.)
4400 Cox Road, Suite 110, Glen Allen, Virginia
23060
(Address of Principal Executive Offices)
 
(Zip Code)
 

(888) 482-8068
Registrant’s telephone number, including area code

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of exchange on which registered
Common StockASGNNYSE
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 1.01. Entry into a Material Definitive Agreement.

On July 31, 2025 (the “Effective Date”), ASGN Incorporated (the “Company”) entered into the Second Amendment to its Third Amended and Restated Credit Agreement (the “Second Amendment”), by and among the Company, the lenders party thereto and Wells Fargo Bank, National Association, as administrative agent. The Second Amendment amends the Company’s existing Third Amended and Restated Credit Agreement, dated as of August 31, 2023 (as amended, restated, supplemented and otherwise modified to date, the “Existing Credit Agreement”) by providing an incremental term loan facility (the “Incremental Term A Loans”) in an aggregate principal amount of $100.0 million, which was borrowed in full on the Effective Date.

The Incremental Term A Loans bear interest, at the Company’s option, at base rate plus a spread of 0.50% to 1.50% or an adjusted term SOFR rate (based on one, three or six-month interest periods) plus a spread of 1.50% to 2.50%, in each case with such spread being determined based on the Company’s consolidated secured leverage ratio. The base rate means the highest of the prime rate, the federal funds rate plus a margin equal to 0.50% and the adjusted term SOFR rate for a 1-month interest period plus a margin equal to 1.00%. Interest is due and payable in arrears (a) quarterly for Incremental Term A Loans bearing interest at the base rate and (b) at the end of an interest period (or at each three-month interval in the case of loans with interest periods greater than three months) in the case of Incremental Term A Loans bearing interest at the adjusted term SOFR rate. The Company (a) is required to make quarterly amortization payments of $625,000 with respect to the Incremental Term A Loans for the first four fiscal quarters ending after the Effective Date, and of $1,250,000 for each fiscal quarter thereafter and (b) paid other customary fees and costs in connection with the Incremental Term A Loans. In addition, the Company must maintain a consolidated secured leverage ratio of not greater than 3.75 to 1.00. The maturity date for the Incremental Term A Loans is February 14, 2028.

Consistent with the Existing Credit Agreement, the Company’s obligations in respect of the Incremental Term A Loans are secured by substantially all of the Company’s assets, subject to customary exceptions, and guaranteed by the material domestic subsidiaries of the Company.

Use of Proceeds. The increased liquidity provided by the Incremental Term A Loans enhances the Company’s financial flexibility, allowing the Company to strategically allocate future cash flows in a manner that serves the best interests of stockholders, including organic investments in the business, creating additional availability under the Company’s current $500 million Senior Secured Revolving Credit Facility (due 2028) for future acquisitions, and buying back shares.

The Incremental Term A Loans are otherwise subject to the same terms and conditions as those set forth in the Existing Credit Agreement, including but not limited to representations and warranties, events of default, and affirmative and negative covenants.

The foregoing description of the Second Amendment is only a summary and is qualified in its entirety by reference to the full text of the Second Amendment, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits
Exhibit NumberDescription
10.1
104.1Cover page interactive data file (embedded within the Inline XBRL document)

Schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted schedules to the SEC upon its request.







SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ASGN Incorporated
Date: July 31, 2025/s/ Marie L. Perry
Marie L. Perry
Executive Vice President and Chief Financial Officer





From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Everforth Inc (EFOR)

Reference

Frequently asked questions

When did Everforth Inc file this 8-K?
Everforth Inc (EFOR) filed this Current Report (Form 8-K) with the SEC on July 31, 2025. The accession number assigned by EDGAR is 0000890564-25-000042.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
ASGN borrows $100M incremental term loan under its credit facility, boosting liquidity for investments, acquisitions, and buybacks; due 2028. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Everforth Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Everforth Inc has filed under CIK 890564, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer